Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Limited has updated its proposed securities issuance, notifying the ASX of changes to the structure of warrants being offered. The face value of each warrant has been amended to AUD 1,000, and the number of warrants to be issued has increased from 4 to 2,000, while the aggregate value of the warrants remains unchanged.
The update, which follows an earlier announcement on 25 February 2026 and aligns with a notice of extraordinary general meeting issued on 19 March 2026, reflects a restructuring rather than an expansion of the financing. This adjustment may improve market accessibility and clarity around the capital raising terms without altering the overall size of the warrant-based funding for the company.
The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code CHM. The company operates in the therapeutics sector, focusing on developing medical treatments, with capital markets activity supporting its research and development and growth plans.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
See more data about CHM stock on TipRanks’ Stock Analysis page.